Hitachi High-Technologies and QIAGEN Sign Agreement
Hitachi High-Technologies’ history of partnerships with instrument providers includes Applied Biosystems (now Thermo Fisher Scientific) for Sanger sequencers and the SOLiD NGS system, and Base4 for nanopore sequencing (see IBO 7/15/13). For diagnostics, it has worked with Roche and bioMérieux.
Tokyo, Japan and Hilden, Germany 6/18/15—Hitachi High Technologies and QIAGEN have entered into a long-term strategic collaboration for molecular testing for life science and IVD. Hitachi High-Technologies will contribute its instrument development and manufacturing technologies, while QIAGEN will provide molecular sample-to-insight solutions. Initially, the collaboration will focus on automated systems for PCR and NGS. The partnership could be expanded to include co-commercialization in certain geographic markets. “Hitachi High-Technologies is a recognized leader in industrial automation and has a proven track record of innovation as well as a significant presence in the Asia-Pacific region,” stated Thierry Bernard, senior vice president, head of Molecular Diagnostics at QIAGEN.
